Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12209188 | 0.87 | KMT2A (0.35) | KMT2AADORA3 | |
| SCHEMBL21061380 | 0.86 | GLP1R (0.30) | GLP1R | |
| SCHEMBL195356 | 0.81 | MAPK1 (0.37) | KMT2AADORA3 | |
| SCHEMBL31670505 | 0.81 | ADORA3 (0.35) | KMT2AADORA3 | |
| SCHEMBL20838959 | 0.77 | JAK2 (0.38) | KMT2AADORA3 | |
| SCHEMBL20838961 | 0.76 | EHMT2 (0.31) | — | |
| SCHEMBL8256742 | 0.74 | BRD4 (0.38) | — | |
| SCHEMBL4071388 | 0.74 | TDP1 (0.36) | KMT2A | |
| SCHEMBL516223 | 0.74 | TDP1 (0.36) | KMT2A | |
| SCHEMBL21098222 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | GLP1R 513/4885CD38 607/4885KMT2A 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.